Figure 4: In vivo imaging of the miR126 NIR MB from the CB-EPCs-treated ischemia. a) In vivo fluorescence imaging of the miR126 NIR MB (1st column), laser Doppler imaging (2nd column) and video image (3rd column) from the CB-EPCs-treated hind limb ischemia mouse for 6 days. The miR126 NIR MB transfected into 2×106 of CB-EPCs was seeded into a matrigel then implanted into the unilateral hind limb ischemia mouse (indicated by a white (2nd column) or black (3rd column) arrow). b) ROI analysis of the in vivo fluorescence activity of the miR126 NIR MB from the 1st column of Figure 5A and Figure S1A. Data were displayed as mean ± standard error (*P<0.05). c) Anatomy analysis of the CB-EPCs-treated hind limb ischemia 6 days after the implantation. The implanted region of the CB-EPCs-incorporated matrigel was magnified by a white circle. CB-EPCs in the matrigel formed vascular tubes that were connected to the host circulation. CB-EPCs were able to produce a dense network of blood vessels that were distributed uniformly throughout the matrigel. d) Double Immunohistochemistry staining of CD31 and vWF in the CB-EPC-treated hind limb ischemia. Confocal microscopy images (X400) of the slice sectioned from the CB-EPC-incorporated matrigels isolated from the CB-EPC-treated hind limb ischemia were conducted using CD31 (yellow) and vWF (green) antibodies. Blue fluorescence represented DAPI which stained the nucleus. Red fluorescence represented the miR126 NIR MB.